Pfizer Moat Analysis: Score & Risks
Pfizer Ltd.
A first-pass moat teardown of Pfizer Ltd., built from single-pass filing evidence. Free note — provisional, and the full two-pass deep dive may revise it.
First-pass narrow read — primary edge in Network Effects. Provisional, single-pass evidence.
Pfizer Ltd. scores 5.2 on MoatSCORE 6.0 — a narrow moat in Pharma. This is a first-pass note: the dimensional read and the filing receipts below come from a single GFIP evidence pass, not the full two-pass deep corpus behind our flagship deep dives. Provisional — published free while the deep version is queued.
Seven dimensions of moat
Ordered by contribution. Each dimension carries a verified filing quote, graded [M] mechanism or [O] outcome.
“Our extensive portfolio reaches over 200,000 Healthcare Providers, ~1,800 Government & Private Hospitals, and over 250,000 retail pharmacies, touching ~300 million patient lives annually.”
“please note, over the last six years, we have not touched the price, we have kept it the same.”
“We launched a global patented product in India called XELJANZ which is a Rheumatoid Arthritis product this quarter”
“Goa site has initiated energy conservation projects which resulted reduction of Electrical power consumption by 15% over previous year.”
“There is actually a one-time provision of about Rs.13 crores which is sitting in the material cost because of the discontinuation that we announced for manufacture of Corex.”
“But otherwise patients who are on Eliquis they continue to take medicines on compliance. So we have not really seen that level of impact on Eliquis as compared to the hospital products or vaccine products.”
D8 rating: ADEQUATE. Not part of the moat score — it governs the cost of equity and the fade window. First-pass; not yet deep-reviewed.
The barrier gate — first-pass
Effective barrier 6 — at or above 6, consistent with a narrow read. First-pass estimate.
Deep two-pass review. This draft rests on a single GFIP evidence pass; the full 10-year AR + concall corpus may move the read.
The barrier gate. A firmer replication or bypass estimate is the most likely thing to shift the band.
Adverse events. Any governance, regulatory or funding shock captured in D8 could re-rate the fade window.
Where this note fits. This company is one of 509 Indian companies we have scored for moat durability — 370 narrow, 126 narrow-trending-wide, none wide. Every score, dimension by dimension, is free in the Moat Screener.
Member discussion